# Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

Source: https://onco.cc/trials/nct05997017/  
OnCo record `nct05997017` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Sirolimus protein-bound particles in endometrial cancer, run by Aadi Bioscience, Inc., now recruiting.

## Summary

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer is a phase 2 interventional study registered as NCT05997017 by Aadi Bioscience, Inc., with 29 participants planned, started 2023-12-28 and due to reach its primary completion in 2026-12. Interventions recorded: nab-sirolimus. Conditions listed: Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05997017
- Phase: 2
- Setting: A Phase 2 Multi-center Open-label Trial of Nab-Sirolimus in Combination With Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
- Sponsor: Aadi Bioscience, Inc.
- Enrolled: 29

## Sources

- ClinicalTrials.gov NCT05997017: https://clinicaltrials.gov/study/NCT05997017

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- drugs: [Sirolimus protein-bound particles](https://onco.cc/drugs/sirolimus-albumin-bound/)

---
JSON: https://onco.cc/api/v1/entities/nct05997017.json